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Abstract
Maresins are a new family of anti-inflammatory and pro-resolving lipid mediators biosynthesized from docosahexaenoic
acid (DHA) by macrophages. Here we identified a novel pro-resolving product, 13R,14S-dihydroxy-docosahexaenoic acid
(13R,14S-diHDHA), produced by human macrophages. PCR mapping of 12-lipoxygenase (12-LOX) mRNA sequence in
human macrophages and platelet showed that they are identical. This human 12-LOX mRNA and enzyme are expressed in
monocyte-derived cell lineage, and enzyme expression levels increase with maturation to macrophages or dendritic cells.
Recombinant human 12-LOX gave essentially equivalent catalytic efficiency (kcat/KM) with arachidonic acid (AA) and DHA as
substrates. Lipid mediator metabololipidomics demonstrated that human macrophages produce a novel bioactive product
13,14-dihydroxy-docosahexaenoic acid in addition to maresin-1, 7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic
acid (MaR1). Co-incubations with human recombinant 12-LOX and soluble epoxide hydrolase (sEH) demonstrated that
biosynthesis of 13,14-dihydroxy-docosahexaenoic acid (13,14-diHDHA) involves the 13S,14S-epoxy-maresin intermediate
produced from DHA by 12-LOX, followed by conversion via soluble epoxide hydrolase (sEH). This new 13,14-diHDHA
displayed potent anti-inflammatory and pro-resolving actions, and at 1 ng reduced neutrophil infiltration in mouse
peritonitis by ,40% and at 10 pM enhanced human macrophage phagocytosis of zymosan by ,90%. However, MaR1
proved more potent than the 13R,14S-diHDHA at enhancing efferocytosis with human macrophages. Taken together, the
present findings demonstrate that macrophages produced a novel bioactive product identified in the maresin metabolome
as 13R,14S-dihydroxy-docosahexaenoic acid, from DHA via conversion by human 12-LOX followed by sEH. Given its potent
bioactions, we coined 13R,14S-diHDHA maresin 2 (MaR2).
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Introduction
The acute inflammatory response is the host protection against
harmful stimuli, including pathogen infections, irritants and cell
damage [1]. New families of lipid mediators, derived from n-3
polyunsaturated fatty acid (PUFA), that are biosynthesized during
the resolution phase of acute inflammation and coined resolvins and
protectins, were uncovered that potently stop inflammation
promoting catabasis and return to homeostasis [2]. Macrophages
play a centralroleinresolution, woundhealing andtissuerepair[3].
Maresins, macrophage mediators in resolving inflammation, are a
family oflipid mediatorsbiosynthesizedbymacrophagesfromDHA
via human 12-lipoxygenase (12-LOX) [4]. Maresin 1 (7R,14S-
dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid or Ma
R1), the first member of this family identified, displays potent
anti-inflammatory and pro-resolving actions inhibiting neutrophil
infiltration in vivo, and stereoselectively stimulating macrophage
phagocytosis and efferocytosis [4,5]. The complete stereochemistry
of MaR1 has been established, and MaR1 also displays potent tissue
regenerative as well as anti-nociceptive actions [5].
Biosynthesis of maresins in macrophages involves an initial
oxygenation of DHA with molecular oxygen [4], followed by
epoxidation of the 14 hydroperoxy-intermediate that is subse-
quently converted to 13S,14S-epoxy-maresin [6]. Evidence for
13S,14S-epoxy-maresin was recently obtained from both human
macrophages [4] and recombinant human 12-LOX incubation [6]
using alcohol trapping. The complete stereochemistry of this
epoxide intermediate was determined, 13S,14S-epoxy-docosa-
4Z,7Z,9E,11E,16Z,19Z-hexaenoic acid, by total organic synthesis
as well as its biological actions were uncovered [6].
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e102362Given the potent pro-resolving actions of MaR1 [4,5], it
remained of interest to characterize the role of human 12-LOX in
macrophages in maresin biosynthesis, and whether 13S, 14S-
epoxy-maresin intermediate is converted to additional bioactive
products by human macrophages. Here, we characterized the
human macrophage 12-LOX and its role in maresin biosynthesis,
and identified a new bioactive macrophage product (13R,14S-
dihydroxy-4Z,7Z,9E,11E,16Z,19Z-hexaenoic acid) coined MaR2
that displays anti-inflammatory and pro-resolving actions.
Materials and Methods
Materials
RPMI 1640 and DPBS (with or without calcium and
magnesium) were purchased from Lonza (Hopkinton, MA,
USA). Ficoll-Histopaque 1077-1, lipopolysaccharide (LPS) and
zymosan A were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Human recombinant granulocyte-monocyte colony stimu-
lating factor (GM-CSF), macrophage colony simulating factor,
interferon c (IFN-c) and interleukin-4 were purchased from R&D
System (Minneapolis, MN, USA). Fetal calf sera, ampicillin and
bac-to-bac baculovirus expression system were from Invitrogen
(Grand Island, NY, USA). High capacity cDNA reverse
transcription kit was from Applied Biosystems (Grand Island,
NY, USA). Phusion PCR kit and cloning enzymes were from New
England BioLabs (Ipswich, MA, USA). All primers were
synthesized by Integrated DNA Technologies (Coralville, IA,
USA). Bio-scale Mini Macro-prep High Q columns were from
BioRad (Hercules, CA, USA). Sephacryl S-100 HR resin was from
GE Life Sciences (Pittsburgh, PA, USA). FACS analysis antibodies
against the surface marks were from BioLegend (San Diego, CA,
USA). FITC rat anti-mouse Ly6G (clone IAS), purified rat anti-
mouse CD16/32 (mouse BD Fc block) were purchased from BD
Bioscience (San Jose, CA), and PE rat anti-mouse F4/80 (clone
BM8) and PerCPCy5.5 rat anti-mouse CD11b (clone Mac-1) were
purchased from eBioscience (San Diego, CA). Human 12-
lipoxygenase monoclonal antibody was from Novus Biologicals
(Littleton, CO, USA). Human soluble epoxide hydrolase poly-
clonal antibody, soluble epoxide hydrolase, AA, DHA, d8-5S-
HETE and d4-LTB4 purchased were from Cayman Chemicals
(Ann Arbor, MI, USA). Human soluble epoxide hydrolase shRNA
constructs were from OriGene (Rockville, MD, USA). C18 SPE
columns were from Waters (Milford, MA, USA). Eclipse Plus C18
column was from Agilent (Santa Clara, CA, USA). All liquid
chromatography solvents were from Fisher Scientific (Pittsburgh,
PA, USA).
Human macrophage and dendritic cell preparation
Human peripheral blood mononuclear cells (PBMC) from
whole blood (purchased from Children’s Hospital Blood Bank,
Boston, MA, de-identified from healthy donors) were isolated by
density gradient centrifugation using Histopaque-1077. Monocytes
(MC) were obtained by adhesion purification, and were cultured in
RPMI with 10 ng/mL human recombinant GM-CSF at 37uC for
7 days to obtain macrophages (M0). M1 macrophages were
obtained by stimulating M0 macrophages with 20 ng/ml IFN-c
and 1 ng/ml LPS for 24 h. M2 macrophages were obtained by
incubating monocytes with 20 ng/ml macrophage colony simu-
lating factor for 6 days and stimulating with 20 ng/ml IL-4 for
48 h [7]. Immature dendritic cells (iDC) were obtained by
incubating isolated MCs with 50 ng/ml GM-CSF and 34 ng/ml
IL-4 for 7days, and mature dendritic cells (mDC) were stimulated
by 100 ng/ml LPS for 24 h [8]. Phenotypic lineage of monocyte-
derived cells was confirmed by flow cytometry staining with
fluorescent-conjugated antibodies, including CD163, CD54 and
CD80 [7].
Quantitative real-time PCR (qPCR)
Total RNA was isolated from cultured cells using High Pure
miRNA Isolation Kit (Roche), and cDNA was synthesized with
High Capacity Reverse Transcription Kit (Applied Biosystems)
according to the manufacturer’s protocol. Real-time PCR was
performed using the SYBR-green [9]. GAPDH was employed as
internal control. Expression was measured on an ABI Prism cycler
(Applied Biosystems, Foster City, CA) and data were analyzed using
the DDCt method. The forward and reverse primers used were as
follows: 12-LOX (59-GATGATCTACCTCCAAATATG-39 and
59-CTGGCCCCAGAAGATCTGATC-39) and GAPDH (59-AG-
CCACATCGCTCAGACAC-39 and 59-GCCCAATACGACCA-
AATCC-39).
Cloning of human macrophage 12-lipoxygenase
12-LOX cDNA was synthesized with high capacity cDNA
reverse transcription kit (Applied Biosystems) and a 12-LOX
specific RT primer from M0 macrophage total mRNA. The
primer sequence is 59-AGA AAG TTT ACT GCT CCC CTG G-
39. Two pairs of primers were designed to amplify the upstream
and downstream regions. The two regions cover the whole coding
area of 12-LOX cDNA and had ,200 bp overlap. The upstream
primer sequences were: 59-CTC CCC TCG CCT AAG CTG
CTG-39;5 9-CTT GAA GAT GGG GTG CAG TCC-39. The
downstream primer sequences are: 59-ATT CAG CCT CCC
AAC CCC AGC TCT-39;5 9-GGT TTA ACT GGG GGA GGA
AAT AGA GCC T-39. PCRs were performed with Phusion PCR
kit (New England BioLabs) following manufacturer’s instruction to
amplify the upstream and downstream regions. Human 12-LOX
full-length cDNA coding 663 amino acid residues was obtained by
using the obtained upstream-downstream PCR products as
template, and performing a second round of PCR (SOEing
PCR). NdeI and BamHI restriction sites were included in front of
start codon and after stop codon, respectively. 12-LOX full-length
cDNA was inserted into pET20b vector and sequenced.
Expression of human macrophage 12-LOX protein in sf9
cells
12-LOX protein was obtained with Bac-to-Bac Baculovirus
Expression System (Invitrogen) and the manufacturer’s instruc-
tions. In brief, 12-LOX cDNA was sub-cloned into pFastBac
vector. pFastBac-12-LOX plasmid was transformed into
DH10Bac E. coli, and was recombined with bacmid. The
fragment with 12-LOX was donated into bacmid. The bacmid
harboring 12-LOX was isolated and transfected into insect sf9
cells. After 5 days, the first generation virus (P1) was harvested
from the media. 0.5 to 1 ml of P1 was used to infect 10 ml of sf9
cells to obtain the second generation of virus (P2). 125 ml of sf9
cells with density of 2610
6 cells/ml in suspension culture were
infected with 10 ml P2 at 27uC for 72 h. Cells were stored at 2
80uC after centrifugation at 2000 g for 10 min.
Protein purification
Sf9 cells were suspended in 50 mM Tris-HCl (pH 8) buffer
supplemented with protease inhibitor cocktail (sigma), and
disrupted by sonication (Branson, 20 s pulse for 5 times). Soluble
fraction was isolated by centrifugation at 15000 g for 30 min for
column chromatography. 12-LOX protein was purified to
homogeneity by ion exchange and size exclusion column
chromatography consecutively using Bio-scale Mini Macro-prep
Human Macrophage 12-Lipoxygenase in Maresin 2 Biosynthesis
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rate of 1.0 and 0.35 ml/min, respectively. For Q column, a linear
gradient between 0 and 1 M NaCl in 50 mM Tris-HCl (pH 8) was
used to elute all proteins in 20 column volumes. The fractions with
12-LOX activity (see next section) were collected, pooled,
concentrated and loaded onto Sephacryl S-100 HR column with
50 mM Tris-HCl (pH 8). All procedures were conducted on ice or
at 4uC. Protein purity was determined to be about 90% by SDS-
PAGE. Small aliquots of concentrated human recombinant 12-
LOX were flash frozen in liquid nitrogen and stored at 280uC
until use.
Kinetic assays
Assays were performed using a Cary 60 UV-Vis spectrophotom-
eter. Either AA or DHA from 1 mMt o5 0mM was used as substrate
[S], and 12-LOX concentration [E] was fixed at 100 nM. Assays
were conducted either in calcium-depleted buffer (50 mM Tris,
pH 8, 1 mM EGTA, 2 mMMgCl2, 0.03% Tween 20) or in calcium-
supplemented buffer (50 mM Tris, pH 8.0, 1 mM EGTA, 2 mM
MgCl2, 3 mM CaCl2, 0.03% Tween 20). Conversion of AA to
HpETEs or DHA to HpDHA was monitored by UV absorbance at
235–236 nm. At each given substrate concentration, initial rate (V0)
was obtained using extinction coefficient e236<23,000 M
21cm
21.V 0
and substrate concentration [S] were fit into Michaelis-Menten
equation: V0=[E] 6kcat6[S]/(KM+[S]) to determine KM and kcat.
Mouse peritonitis
All animal procedures were approved by the Standing
Committee on Animals of Harvard Medical School (Protocol
02570) and performed in accordance with institutional guidelines.
Male FVB mice (6–8 weeks old, weighing 22–25 g) were
purchased from Charles River Laboratories. Mice were housed
4 mice per cage in specific pathogen-free facilities in a humidity
(45–55%) and temperature (23–25uC) controlled environment
with a 12 h light-dark cycle. Mouse peritonitis was carried out as
in [10] and efforts were made to minimize suffering (e.g. if an
increase in pain or stress behavior was noted, the mice were
euthanized according to Protocol #02570). Briefly, mice were
anesthetized by inhaled isofluorane according to Protocol 02570
and randomly assigned to be administered intravenously with 1 ng
13R,14S-diHDHA, MaR1, or vehicle (saline) immediately prior to
the administration of 0.1 mg zymosan [11]. At 4 h, mice were
euthanized with overdose of isoflurane followed by cervical
dislocation and peritoneal lavages collected. PMN numbers were
assessed by light microscopy and flow cytometry. PMNs were
identified as CD11b
+ and Ly6G
+ cells.
Human macrophage phagocytosis
Human M0 macrophages were plated onto 96-well plates
(5610
4 cells/well) and phagocytosis was carried out after 24 h.
Cells were incubated with either vehicle (PBS containing 0.1%
ethanol), MaR1 as in [4,5] or 13R,14S-diHDHA at indicated
concentrations (15 min, 37uC). All incubations were conducted in
PBS containing calcium and magnesium (PBS
+/+). Subsequently
either FITC-labeled zymosan (5610
5 particles/well) or fluorescent
labeled apoptotic PMN (1.5610
5 cells/well) were added to each
well and cells incubated for a further 60 min at 37uC, pH 7.45.
The cells were washed 3 times with PBS
+/+ and extracellular
fluorescence was quenched using Trypan Blue (1:15 diluted).
Phagocytosis was assessed using a SpectraMax M3 plate reader
(Molecular Devices).
Human recombinant enzyme incubations
To identify the chirality of 12-LOX product(s), DHA (5 mM)
was mixed with the isolated human macrophage 12-LOX
(0.2 mM) in 100 mL 20 mM Tris (pH 8), 100 mM KCl at 37uC
for 10 min. In select incubations, DHA (10 mM) was either
incubated with human 12-LOX or with 12-LOX plus sEH
(0.28 mM) in the same Tris buffer as above at 37uC, pH 8.0 for
10 min. All incubations were stopped by 2 volumes of methanol,
and 500 pg d8-5S-HETE and d4-LTB4 were added into each
sample before extraction as internal standards [12].
Sample extractions and LC-MS/MS
All samples from recombinant enzyme incubations were
subjected to liquid-liquid extractions with 6 volumes of diethyl
ether. The samples from cell incubations were extracted with SPE
columns [12]. LC-MS/MS analyses were conducted as in [6]. In
the chiral chromatography separation, Chiralpak AD-RH column
was used with methanol/water/acetic acid of 95:5:0.01 (v/v/v)
[13]. The transition ion pairs were: 14-hydroxy-
4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid (14-HDHA)
(343.205) and 13,14-diHDHA (359.221). 500 pg d8-5S-HETE
and d4-LTB4 were used as internal standards to determine
extraction recoveries.
Figure 1. Human macrophages and dendritic cells express human 12-LOX. (A) Expression levels of 12-LOX mRNA in human monocytes
(MC), M0, M1, M2 macrophages, immature dendritic cells (iDC) and mature dendritic cells (mDC) were assessed by quantitative PCR. (B) 12-LOX
protein expression levels were assessed by flow cytometry. In the left panel, a representative histogram shows 12-LOX present in each cell type. In the
right panel, results are mean fluorescent intensity (MFI) of 12-LOX protein levels for each cell type, expressed as mean6SEM of 4 separate cell
preparations (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0102362.g001
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The procedure was modified from [14]. In brief, cell lysis was
mixed with equal volume of tricine sampling buffer (BioRad), and
mixtures were immediately boiled at 95uC for 4 min. The samples
were loaded to 10% SDS-PAGE, and was transferred to
nitrocellulose membranes after gel separation. Membranes were
probed by primary and secondary antibodies consecutively.
Primary antibodies were diluted as instructions: 1:500 for anti-
human 12-LOX (Novus Biologicals); 1:200 for anti-human sEH
(Cayman); 1:200 for anti b-actin (Santa Cruz). Blots were
developed by enhanced chemiluminescence (Pierce).
Statistics
All the results were expressed as means 6 standard error. One-
way ANOVA was carried out to determine difference between
groups. P,0.05 was considered significant.
Results
Human monocyte-derived lineage express 12-LOX
We first examined 12-LOX expression levels in human
monocytes (MC), macrophages (M0, M1 and M2) and dendritic
cells (DC). The cells were prepared in accordance with published
methods [7,8]. Quantitative PCR results using the human platelet
12-LOX sequences as primers (see methods) gave rather low 12-
LOX mRNA levels in MC, M0, M1 and M2 cells as well as iDCs
(immature dendritic cells) (Fig. 1a). In contrast, the 12-LOX
mRNA level in mDC (mature dendritic cells) was significantly
higher, or about 3.5 fold compared to iDC. Also, flow-cytometry
assessment using fluorescence-labeled antibody against human 12-
LOX demonstrated about 10 fold increase in protein expressions
in M0, M1 M2 and iDC, and 19 fold increase in mDC, compared
to MC (Fig. 1b), indicating that expression of human 12-LOX
protein is enhanced with differentiation of MC to macrophages
and dendritic cells. Cell lineage was determined by flow cytometry
using distinct phenotypic markers (CD80 for M1, CD163 for M2,
CD54 for DC, Fig. S1) [7].
We amplified 24-1214 and 1005–2167 bp fragments of 12-
LOX from human macrophages (M0) cDNA (Fig. S2). The two
fragments covered the entire coding area, and had about 200 bp
overlapping. We numbered nucleotides in the present report on
the basis of the platelet cDNA sequence [15]. We obtained the full
length of human macrophage 12-LOX cDNA by SOEing PCR
with the 24–1024 and 1005–2167 fragments as template, and the
sequencing results showed that M0 12-LOX cDNA sequence was
in accordance with that reported earlier for human platelet 12-
LOX [15] (see Fig. S2). Also, western blotting for 12-LOX
revealed 75 kD size bands in macrophages and dendritic cell,
which is consistent with the size of human platelet 12-LOX (Fig.
S2).
Human macrophage recombinant 12-LOX converts DHA
and AA with essentially equivalent catalytic efficiency
We next examined and compared the catalytic efficiencies of
AA and DHA with human macrophage recombinant 12-LOX.
AA or DHA were incubated with 0.1 mM human recombinant
macrophage 12-LOX in the presence or absence of CaCl2. The
initial rate at each substrate concentration was plotted and fit to
Michaelis-Menten equation using non-linear regression to deter-
mine kcat (maximal turnover rate per enzyme) and KM (concen-
tration of substrate with initial rate reaching half of maximal rate,
Fig. 2, Table 1). The calculated kcat for DHA was 2 fold lower
than AA; however, the calculated KM for DHA was about 2 fold
lower than that of AA, suggesting that the maximal turnover of
DHA by 12-LOX is slower, while affinity of DHA to 12-LOX is
higher when compared to AA. The resulting catalytic efficiencies,
indicated by kcat/KM, were essentially equivalent between DHA
and AA. Also, addition of CaCl2 appeared to increase both kcat
and KM, yet lead to no significant increase in catalytic efficiency
(kcat/KM)( Table 1).
Stereo and positional selective production of 14S-HpDHA
by human macrophage 12-LOX
Recombinant human macrophage 12-LOX was expressed with
baculovirus-insect system, and was purified to apparent homoge-
neity as described in methods. DHA was incubated with human
macrophage 12-LOX. After reduction of reaction mixture using
NaBH4, the hydroxyl-containing products were separated using
chiral high performance liquid chromatography and identified
using lipid mediator metabololipidomics. We found that in these
incubations the peak at retention time of ,6 min accounted for
,98% peak area and matched the retention time of 14S-HDHA
(Fig. 3a). The MS-MS spectrum for the product beneath this peak
matched that of 14-HDHA (Fig. 3b). These results demonstrate
that human macrophage 12-LOX inserted oxygen at the C-14
position of DHA predominantly in the S conformation.
Identification of endogenous 13,14S-diHDHA from
human macrophages
We next investigated whether the 13S,14S-epoxy-maresin, a
biosynthetic product of human macrophage 12-LOX [6], was
converted by human macrophage to novel products. Using lipid
mediator metabololipidomics, we identified 2 endogenous prod-
ucts from macrophages with the fragmentation spectrum for the
product under peak I matching 13,14S-diHDHA with the
following ions assigned: m/z 359=M-H, m/z 341=M-H-H2O,
m/z 323=M-H-2H2O, m/z 315=M-H-CO2, m/z 297=M-H-
H2O-CO2, m/z 279=M-H-2H2O-CO2, m/z 203=221-H2O, m/z
177=221-CO2, m/z 149=167-H2O, and m/z 147=191-CO2
(Fig. 4). Peak II with retention time of 6.5 min displays the
essentially identical fragmentation to peak I, and thus suggests that
the product beneath peak II was a stereoisomer of peak I.
Figure 2. Human 12-LOX converts AA and DHA with essentially
equivalent efficiency. Increasing concentrations of AA or DHA (1 to
50 mM) were mixed with 12-LOX (0.1 mM, pH 8.0, R.T.) in the presence or
absence of CaCl2 (2 mM). Initial rates were monitored and plotted
versus substrate at indicated concentrations. Each point represents
mean6SEM from n=3 separate experiments.
doi:10.1371/journal.pone.0102362.g002
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KM (mM) kcat (min
21)k cat/KM (min
21 mM
21)
AA 9.762.1 80.366.0 8.3
DHA 5.160.7 40.461.6 7.9
AA+Ca
2+ 12.662.2 109.467.1 8.7
DHA+Ca
2+ 7.162.0 70.266.1 9.9
*Initial rate at each substrate concentration was fitted into Michaelis-Menten equation to determine KM and kcat. Results are mean 6 SEM.
doi:10.1371/journal.pone.0102362.t001
Figure 3. Human macrophage 12-LOX produces 14S-HpDHA.
(A) Chiral chromatography of synthetic 14R-HDHA and 14S-HDHA
(upper panel). DHA (5 mM) was incubated with human macrophage 12-
LOX (0.2 mM, 10 min, 37uC, pH 8). Products were extracted (see
methods for details) and subject to chiral high performance liquid
chromatography-tandem mass spectrometry (m/z, 343.205) (lower
panel). (B) MS-MS spectrum of 14S-HDHA from human macrophage 12-
LOX incubations (lower panel in A).
doi:10.1371/journal.pone.0102362.g003
Figure 4. Human macrophage endogenous production of
13R,14S-diHDHA. (A) MRM chromatography for ion pair 359.221
(m/z). Human macrophages were incubated with opsonized zymosan
(DPBS+/+, pH 7.45, 15 min, 37uC). Incubations were stopped with 2
volumes of ice-cold methanol, and products were assessed by lipid
mediator metabololipidomics. (B) MS-MS spectra. Inset, diagnostic ions
used for identification and corresponding possessed structure frag-
ments. Results are representative of n=3.
doi:10.1371/journal.pone.0102362.g004
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sEH is expressed in cells of the monocyte lineage [16,17]. sEH
converts leukotriene A4 to 5S,6R-diHETE [18] and epoxyeicosa-
trienoic acids to vicinal diols [19]. Therefore, we next investigated
whether this enzyme was involved in the biosynthesis of 13,14S-
diHDHA. Co-incubation of both human macrophage 12-LOX
and sEH with DHA gave 13,14S-diHDHA (peak II, ,0.1%
conversion) in comparison to scant formation of this diol product
(,0.005% conversion) when only DHA and 12-LOX were present
in the incubations (Fig. 5a). The MS-MS fragmentation of
13,14S-diHDHA (peak II, Fig. 5b) using this recombinant
enzyme system matched those obtained from macrophages
(Fig. 4). In the incubations with 12-LOX and DHA, we also
identified a double oxygenation product (7S, 14S-diHDHA; peak
I, Fig. 5b), whereas, MaR1 was not identified in these
coincubations. These results suggest that 13,14-epoxy-maresin
[6] produced from DHA via 12-LOX is substrate of sEH
producing 13,14S-diHDHA.
13,14S-diHDHA displays anti-inflammatory and pro-
resolving bioactions
We next assessed the potential anti-inflammatory actions of the
novel macrophage product isolated by investigating its ability to
regulate leukocyte response in vivo. Mouse peritonitis was initiated
by i.p. injection of zymosan (0.1 mg/mouse) [11]. Peritoneal
lavages were collected at 4 h and PMN were enumerated by light
microscopy and flow cytometry. Systematic administration of
1 ng/mouse of the 13R,14S-diHDHA prior to initiating peritonitis
reduced PMN infiltration into the peritoneum by ,40%; similar
values were obtained for MaR1 (Fig. 6a). In addition, 13R,14S-
diHDHA also enhanced human macrophage phagocytosis of
zymosan by 90% at a concentration as low as 10 pM, compared to
60% maximal enhancement by MaR1 at 10 nM (Fig. 6b).
However, with human apoptotic PMN and macrophages, the
MaR1 proved more potent than 13R,14S-diHDHA at enhancing
efferocytosis.
Discussion
In the present manuscript, we identified and cloned the human
macrophage 12-LOX involved in the biosynthesis and bioactive
maresin metabolome, and found a new member of the maresin
family produced from DHA. The human macrophage 12-LOX
converted both AA and DHA with essentially equivalent efficiency
to produce the hydroperoxy products, respectively, that were
predominantly in the carbon 14 with S configuration (98% S). A
new 13R,14S-diHDHA was identified from human macrophages
that displayed potent anti-inflammatory and pro-resolving actions.
Production of 13R,14S-diHDHA involved the initial oxygenation
at C-14 followed by 12-LOX-catalyzed epoxidation and subse-
quent hydrolysis via sEH. The proposed biosynthetic schemes of
MaR1 and 13R,14S-diHDHA are summarized in Fig. 7. Given
the potent anti-inflammatory and pro-resolving actions of the new
13R,14S-diHDHA diol and its biosynthesis from the 13S,14S-
epoxy-maresin [6], we coined this product as MaR2.
Maresins are biosynthesized by human macrophages 12-LOX
from DHA. MaR1 is the first member of this family to be
identified [4]. In addition to its anti-inflammatory, pro-resolving
[4], tissue regenerative and anti-nociceptive actions [5,6], MaR1
was recently found to dampen the pro-inflammatory response to
organic dust in bronchial epithelial cells [20], and attenuates
mouse colitis [21]. MaR1 was also identified in human synovial
fluid from rheumatoid arthritis patients [22]. Another related 12-
LOX-derived product, 14S,21R-diHDHA, was shown to enhance
Figure 5. Biosynthesis of 13R,14S-diHDHA in coincubations
with human recombinant 12-LOX and sEH. (A) MRM chromatog-
raphy for ion pair 359.221. DHA (10 mM) was incubated with 12-LOX
(0.2 mM) in the absence or presence of 2 U sEH (20 mM Tris, pH 8.0,
100 mM KCl, 37uC, 10 min). (B) MS/MS spectra employed in the
identification of 13,14S-diHDHA (peak II) and 7S,14S-dihydroxy-
4Z,8E,10Z,12E,16Z,19Z-docosahexaenoic acid (7S,14S-diHDHA) (peak I).
Results are representative of n=3.
doi:10.1371/journal.pone.0102362.g005
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diabetes and renal ischemia/reperfusion injury [23–25]. In the
present manuscript, we identified a novel member of the maresin
family, namely 13R,14S-diHDHA, coined MaR2, that is pro-
duced by the human 12-LOX and sEH in human macrophages.
MaR2 exhibited similar potency to MaR1 in limiting PMN
Figure 6. MaR1 and MaR2 (13R,14S-diHDHA) display potent anti-inflammatory and proresolving actions: direct comparison. (A)
Mouse peritonitis: exudate PMN numbers in vivo. Male mice (6–8 weeks) were administered i.v. MaR1, 13R,14S-diHDHA (1 ng/mouse each) or vehicle
prior to i.p. administration of zymosan (0.1 mg/mouse). Peritoneal exudates were collected, and PMNs enumerated using both light microscopy and
flow cytometry. Results are mean 6 SEM. n=3 mice per treatment from three separate experiments (*P,0.05 vs. vehicle). Enhanced phagocytosis of
(B) opsonized zymosan or (C) apoptotic PMN. Human macrophages were seeded in 96-well plates (5610
4 cells/well) and incubated with vehicle (PBS
containing 0.1% ethanol), MaR1 or 13R,14S-diHDHA (PBS
+/+, pH 7.45, 37uC, 15 min). (B) FITC-labeled zymosan (5610
5 particles/well) or (C)
fluorescently labeled apoptotic PMN (1.5610
5 cells/well) were added and cells incubated for an additional 60 min (pH 7.45, 37uC). Non-phagocytosed
zymosan or apoptotic PMN were washed, extracellular florescence quenched and phagocytosis quantified. Results are mean 6 SEM. n=3 separate
human macrophage preparations (*P,0.05, **P,0.01, ****P,0.0001 vs. vehicle; #P,0.05, ###P,0.001 vs. MaR1).
doi:10.1371/journal.pone.0102362.g006
Figure 7. Proposed biosynthetic scheme for MaR1 and MaR2. Human macrophage 12-LOX converts DHA to the 13S,14S-epoxy-maresin
intermediate, and via soluble epoxide hydrolase this intermediate is converted to MaR2. See text for details and stereochemical assignments.
doi:10.1371/journal.pone.0102362.g007
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orders lower than MaR1 in enhancing human macrophage
phagocytosis of zymosan (Fig. 6). MaR2 also enhanced human
macrophage uptake of apoptotic PMN, but was less potent than
MaR1. These are the key defining bioactions of a pro-resolving
mediator [1,2].
Also, we confirmed that the activities of DHA oxygenation and
epoxidation recently identified [4,6] in human macrophages
originated from 12-LOX. The nucleotide sequence of the human
macrophage 12-LOX was in accordance [cf. ref. 15] with human
platelet type; see Figure S2. Human epidermis also has been
shown to express the same platelet type of 12-LOX [26]. Human
12-LOX oxygenates AA at C-12 with S chirality [27]. In the
present report, we found that human macrophage 12-LOX
oxygenated DHA at the C-14 with a predominant S chirality
(Fig. 3). The 14S-HDHA profiling obtained here was consistent
with that from primary macrophages and DHA [4]. The two-
carbon position shift in DHA compared to AA is consistent with
the tail-first substrate access [28]. In addition, human macrophage
12-LOX displayed an epoxide synthase activity converting 14-
hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid (14-
HpDHA) to 13S,14S-epoxy-maresin, as demonstrated by metha-
nol trapping [6]. This product is a central intermediate in maresin
biosynthesis and production of both MaR1 and MaR2 (Fig. 7).
12-LOX also biosynthesizes lipoxins from leukotriene A4 (LTA4)
[29,30] and this enzyme is susceptible to suicide inhibition by
epoxides, such as with LTA4 [30] or 13S,14S-epoxy-maresin [6].
Interestingly 13S,14S-epoxy-maresin only inhibits conversion of
AA by 12-LOX, while conversion of DHA appeared unaltered [6],
thereby suggesting that 13S,14S-epoxy-maresin exerts a feed-
forward action on the maresin pathway and hence in resolution of
inflammation.
Macrophages play an indispensable role in resolution of
inflammation and re-establishment of homeostasis. M1 macro-
phages, stimulated by IFN-c LPS and GM-CSF, resist to microbial
invasion and enhance inflammatory response [31]. In contrast,
M2 macrophages, differentiated on exposure to IL-4, IL-13 and/
or other cytokines as well as hormones, produce decreased level of
pro-inflammatory cytokines and promote resolution [31,32],
whereas DCs play a key role in the transition between innate
and adaptive immunity [33]. Here, human macrophage 12-LOX
initiates biosynthesis of maresins, and more importantly, is
responsible for the production of 13S,14S-epoxy-maresin. Of
note, 12-LOX mRNA expression levels remain unchanged during
differentiation of human monocytes to macrophages, and in
macrophages, 12-LOX mRNA is not regulated by overnight
stimulations with LPS, multiple cytokines or hypoxia [34]. In
agreement with this, in the present investigation, we did not find
significant difference of 12-LOX mRNA levels in human
monocytes, and M0, M1 and M2 macrophages. However, 12-
LOX mRNA levels in mDC were significantly increased after LPS
stimulation, when compared with iDC (Fig.1). Assessment of 12-
LOX protein expression in M0, M1 and M2 macrophages
demonstrated significantly increasing 12-LOX protein levels when
compared to monocytes (Fig.1), suggesting that translational or
post-translational regulation mechanism also plays a role in
establishing 12-LOX protein level in these cells. Of interest, we
also found that mDC possess the highest 12-LOX protein level
compared to other monocyte-derived lineages examined herein,
suggesting that mDC may be a notable source of maresins that can
exert pro-resolving actions during resolution of inflammation.
Given the potent actions of maresins in resolution and the role
of human macrophage 12-LOX in maresin biosynthesis, we
assessed kinetics of conversion for DHA by 12-LOX, finding that
12-LOX catalyzes AA and DHA with equivalent efficiency
(Table 1). Enzymatic turnover approaches the maximal rate
with incubation of either 50 mM AA or DHA. This is less than the
reported critical micelle concentration for either DHA or AA [35].
Hence, increased dietary levels of DHA are likely to switch to
maresin production and enhance the resolution phase on the
infiltrating macrophages in exudates or by DC at local microen-
vironments in lymphoid tissues and elsewhere in humans.
Conclusions
Results obtained in the present studies with recombinant
enzymatic co-incubations demonstrated that biosynthesis of
13R,14S-diHDHA involves a sEH subsequent to 12-LOX
(Fig. 5). Mammalian sEH protein and its activity are present in
mononuclear cells and macrophages [16,17]. Mammalian sEH
enzymes catalyze hydrolysis of a broad category of epoxides,
including epoxyeicosatrienoic acids [36], LTA4 [18] and even
hepoxilins [37]. Our finding further demonstrated that 13S,14S-
epoxy-maresin is a new substrate for sEH by coincubation of 12-
LOX and sEH with DHA, producing a potent new product
(Fig. 5). Since LTA4 is converted by sEH to 5S,6R-diHETE with
double bond geometry 7E,9E,11Z [38]. Based on this mechanism,
we tentatively assigned the complete stereochemistry of MaR2 as
13R,14S-dihydroxy-4Z,7Z,9E,11E,16Z,19Z-hexaenoic acid (see
Figure 7). Taken together, we identified and cloned a human
macrophage 12-LOX and marked its expression in monocyte
lineage. The enzyme matched the human platelet enzyme cloned
earlier [15,39,40]. We also identified a novel pro-resolving product
from MW, MaR2, and characterized its biosynthesis involving 12-
LOX as well as its bioactions. The present findings provide
additional evidence for the macrophage pro-resolving metabolome
and their potential in regulating inflammation and stimulating
resolution.
Supporting Information
Figure S1 Peripheral blood mononuclear cells (PBMC)
were isolated from human whole blood by density
gradient centrifugation using Histopaque-1077 and
Phenotypic differentiations were obtained by culture
as described in methods. Each lineage was confirmed by flow-
cytometry using the surface markers. Results are representative of
n=4.
(PDF)
Figure S2 (A) Two fragments of h12LOX were obtained by
using cDNA from M0 as template. Two fragments together cover
the entire coding area in h12LOX cDNA with ,200 bp overlap.
(B) Human macrophage 12-LOX cDNA was cloned to pET20b
vector and sequenced. The result matches the platelet type of 12-
LOX sequence. (C) Expression of 12-LOX protein in macro-
phages and DCs was detected by western blotting with anti-human
platelet 12-LOX antibody. 75 kD bands were present in each cell
lineage, and the size is consistent with platelet type.
(PDF)
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